The Waddell Center for Multiple Sclerosis

234 Goodman Street, Cincinnati, Ohio 45219 | (866) 941-UCNI (8264)

Clinical Trials Summary

Topic Study No. Clinical Trial Protocol Investigators
Neuropathic Pain in MS patients FJ1-US-HMFR(b) Neuropathic Pain in MS patients Maria Melanson (PI)
Multiple Sclerosis – Relapsing forms of Multiple Sclerosis 101JC402 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri®: STRATIFY-2 Biogen Idec Protocol Number: 101JC402 Joseph A Nicolas (PI)
Multiple Sclerosis – Relapsing Remitting AC-058B201 Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients wi Maria Melanson (PI)
Multiple Sclerosis – Relapsing Remitting AC-058B202 Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ACT-128800, an oral S1P1 receptor agonist, in patients with relapsing-remitting mu Maria Melanson (PI)
Multiple Sclerosis – Relapsing forms of Multiple Sclerosis ELND002-MS103 A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients with Relapsing Forms of Multiple Sclerosis Maria Melanson (PI)
Multiple Sclerosis – Relapsing forms of Multiple Sclerosis ELND002-MS153 An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients with Relapsing Forms of Multiple Sclerosis Maria Melanson (PI)